FORMULATION AND EVALUATION OF QUERCETIN NANOPARTICLE GEL FOR OSTEOARTHRITIS
Quercetin gel for Osteoarthritis
Objective: To analyze the effects of the topical gel that consists of quercetin nanoparticles on the mono iodoacetate-induced osteoarthritis.
Methods: Injection of lecithin-quercetin into chitosan-tocopheryl polyethylene glycol succinate (TPGS) was used to prepared quercetin nanoparticle. Evaluation parameter for the quercetin nanoparticle including polydispersity index, zeta potential, particle size using particle size analyzer and morphology were executed using a transmission electron microscope. The evaluation of quercetin nanoparticle gel includes organoleptic and also a homogeneity of quercetin nanoparticle gel includes pH and viscosity. Quercetin nanoparticle gel was given for osteoarthritis (OA) animal model. The amount dosage of quercetin nanoparticle used in this study was 0.84, 1.68, and 3.37 mg/g gel. Measurement of the edema volume was conducted on day 7, 14, 21, 28, 35, 42, 49, 56, 63, and 70.
Results: The quercetin nanoparticle gel dosage 1, 2, and 3 could reduce inflammation on two osteoarthritis animal models. On DMM group, 14 d after the treatment, there were significant differences between negative group and dosage 3 (P=0.028) and A. conyzoides extract gel (P=0.015). It has shown that injection of mono iodoacetate intraarticularly significantly increased the volume of edema in all groups that had been given by mono iodoacetate on day 7 to day 28. On the 42 d after administration of quercetin nanoparticle gel, there were significant differences between the normal and dosage 3 group (P= 0.000).
Conclusion: Quercetin nanoparticle gel could reduce inflammation and prevent cartilago damage on histological evaluation.
2. Heldari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and feature: Part I. Caspian J Int Med 2011;2:205-12.
3. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opinion Rheumatol 2011;23:471-8.
4. Likivainio T, Arokoski J. Physical function and properties of quadriceps femoris muscle in men with knee osteoarthritis. Arch Phys Med Rehabil 2008;89:2185–93.
5. Pirmohamed M, James S, Meakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15–9.
6. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus 2017;9:e1144.
7. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.
8. Kelly GS, Gregory S, Kelly ND. Quercetin monograph. Alternative Medicine Review 2011;16:172-94.
9. Lee KM, Hwang MK, Lee DE, Lee KW, Lee HJ. Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem 2010;58:5815–20.
10. Yoon JS, Chae MK, Lee SY, Lee EJ. Anti-inflammatory effect of quercetin in whole orbital tissue culture of graves' orbitopathy. Br J Ophthalmol 2012;1117–21.
11. Wu X, Landfester K, Musyanovych A, Guy RH. Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-23.
12. Tan Q, Liu W, Guo C, Zhai, G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 2011;6:1621-30.
13. Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm 2008;360:184-90.
14. Bahtiar A, Nurazizah M, Roselina T, Tambunan AP, Arsianti A. Ethanolic extracts of baA. conyzoides leaves (Ageratum conyzoides L.) prevents inflammation and proteoglycan degradation by inhibiting TNF-a and MMP-9 on osteoarthritis rats induced by monosodium iodoacetate. Asian Pacific J Trop Med 2017;10:270-7.
15. Mohanraj VJ, Chen Y. Nanoparticles–a review. Trop J Pharm Res 2006;5:561-73.
16. Ahmed SI, Mangamoori LN, Rao YM. Formulation and characterization of matric and triple-layer matrix tablets for oral controlled drug delivery. Int J Pharm Pharm Sci 2010;2:137-43.
17. Wadsworth LT, Kent JD, Holt RJ. Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, four-week study. Curr Med Res Opinion 2016;32:241-50.
18. Choksi AN, Poonwalla T, Wilkerson MG. Nanoparticles: a closer look at their dermal effects. J Drugs Dermatol 2010;9:475-81.
19. Pavelic Z, Skalko Basnet N, Filipovic Grcic J, Martinac A, Jalsenjak I. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Controlled Release 2005;106:34–43.
20. Schubert MA, Harms M, Müller Goymann CC. Structural investigations on lipid NPs are containing high amounts of lecithin. Eur J Pharm Sci 2006;27:226–36.
21. Sonvico F, Cagnani A, Rossi A, Motta S, Di Bari MT, Cavatorta F, et al. Formation of self-organized NPs by lecithin/chitosan ionic interaction. Int J Pharm 2006;324:67-73.
22. Senyigit T, Sonvico F, Barbieri S, Ozer O, Santi P, Colombo P. Lecithin/chitosan NPs of clobetasol-17-propionate capable of accumulation in pigskin. J Controlled Release 2010;142:368-73.
23. Fakhry A, Schneider GB, Zaharias R, Senel S. Chitosan supports the initial attachment and spreading of osteoblast preferentially over fibroblasts. Biomaterials 2004;25:2075-9.
24. Zhu W, Guo C, Yua A, Gao Y, Cao F, Zhai G. Microemulsion-based hydrogel formulation of penciclovir for topical delivery. Int J Pharm 2009;378:152-8.
25. El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil emulsion: effects of cosurfactants. Int J Pharm 2008;355:285-92.
26. Mishra PR, Al Shaal L, Muller RH, Keek CM. Production and characterization of hesperetin nanosuspension for dermal delivery. Int J Pharm 2009;37:182-9.
27. Van Eerdenbrugh B, Van den Mooter G, Augustijn P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization, and transformation into solid products. Int J Pharm 2008;364:64-75.
28. Baert L., van’t Klooster G, Dries W. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009;72:502-8.
29. Liu W, Guo Y. Interaction between flavonoid, quercetin, and surfactant aggregates with different charges. J Colloid Interface Sci 2006;302:625-32.
30. Bahtiar A, Sari FA, Audina M, Datunsolang NLC, Arsianti A. Ethanolic extracts of hedyotis corymbosa L. improves monosodium iodoacetate induce of osteoarthritis in rat. Asian J Pharm Clin Res 2017;10:473-6.
31. Iijima H, Aoyama T, Ito A, Tajino J, Nagai M, Zhang X, et al. Destabilization of the medial meniscus leads to subchondral bone defects and site-specific cartilage degeneration in an experimental rat model. Osteoarthritis Cartilage 2014;22:1036-43.
32. Im JS, Kim XL. Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis Rheumatism 2010;62:2995-3005.
33. Janusz MJ, Hook?n EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoy-Land JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 2001;9:751–60.
34. Permatasari DA, Karliana D, Iskandarsyah, Arsianti A, Bahtiar A. Quercetin prevent proteoglycan destruction by inhibits matrix metalloproteinase-9, matrix metalloproteinase-13, a disintegrin and metalloproteinase with thrombospondin motifs-5 expressions on osteoarthritis model rats. J Adv Pharm Technol Res 2019;10:2-8.
35. Manjeet KR, Ghosh B. Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. Int J Immunopharmacol 1999;21:435–43.
36. Zupanets IA, Shebeko SK, Popov OS. The effect of the medication diclocor containing diclofenac and quercetin, on clinical, biochemical parameters in rats with osteoarthritis. Int J Pharm Pharm Sci 2015;7:101-4.
37. Kim HP, Mani I, Iversen L, Ziboh VA. Effects of naturally occurring flavonoids and bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukotrienes Essential Fatty Acids 1998;58:17–24.
38. Ribeiro D, Freitas M, Tome SM, Silva AM, Laufer S, Lima JL, et al. Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in whole human blood. Inflammation 2015;38:21491-4.
This work is licensed under a Creative Commons Attribution 4.0 International License.